MannKind (MannKind) EBIT per Share : $0.05 (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is MannKind EBIT per Share?

MannKind's EBIT per Share for the three months ended in Dec. 2023 was $0.03. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.05.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for MannKind's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of MannKind was 50.30% per year. The lowest was -18.40% per year. And the median was 25.25% per year.

MNKD's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.4
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

MannKind's EBIT for the three months ended in Dec. 2023 was $8.3 Mil.

MannKind EBIT per Share Historical Data

The historical data trend for MannKind's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MannKind EBIT per Share Chart

MannKind Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

-0.21

-0.22

-0.26

-0.24

0.06

MannKind Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EBIT per Share	Get a 7-Day Free Trial															-0.05	-0.02	0.02	0.02	0.03

MannKind EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

MannKind's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	14.784	/	267.014
=	0.06

MannKind's EBIT per Share for the quarter that ended in Dec. 2023 is calculated as

	EBIT per Share		(Q: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	8.317	/	269.678
=	0.03

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.05

MannKind (NAS:MNKD) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

MannKind EBIT per Share Related Terms

Thank you for viewing the detailed overview of MannKind's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

MannKind (MannKind) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MannKind Corp (NAS:MNKD) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

NNFN:Germany

Address

1 Casper Street, Danbury, CT, USA, 06810

Website

https://www.mannkindcorp.com

MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Executives

Michael Castagna	officer: Chief Commercial Officer	25134 RYE CANYON LOOP, SUITE 300, VALENCIA CA 91355
David Thomson	officer: VP & Assoc General Counsel	28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Steven B. Binder	officer: Chief Financial Officer	30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
Burkhard Blank	officer: EVP Chief Medical Officer	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Lauren M Sabella	officer: EVP Chief Operating Officer	C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Sanjay R Singh	officer: EVP Technical Operations	1 CASPER STREET, DANBURY CT 06810
Alejandro Galindo	officer: Chief Commercial Officer	30930 RUSSELL RANCH RD, STE 300, WESTLAKE VILLAGE CA 91362
Stuart A Tross	officer: Corp VP, Chief People Officer	ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Anthony C Hooper	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Jennifer Grancio	director	30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA 91362
Christine Mundkur	director
Sabrina Kay	director	30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
David M Kendall	officer: Chief Medical Officer	30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362
Patrick Mccauley	officer: Chief Commercial Officer	30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
Barton Courtney	officer: Chief Compliance Officer	30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362